Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1256)
  2. Journal Article (1061)
  3. Review (108)
  4. Editorial (54)
  5. Research Letter (31)
  6. Book Section (22)
  7. Correspondence (20)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (2470)
  2. Solid Tumor Oncology Division (1885)
  3. Hematologic Malignancies, Division of (1191)
  4. GSK Faculty (1125)
  5. Department of Pathology and Laboratory Medicine (917)
  6. Epidemiology and Biostatistics (863)

More Groups

People
  1. Michael Berger (215)
  2. Marc Ladanyi (191)
  3. Pedram Razavi (184)
  4. Michael Offin (173)
  5. David Solit (166)
  6. Maria Carlo (166)

More People

Years
  1. 2025 (152)
  2. 2024 (370)
  3. 2023 (292)
  4. 2022 (347)
  5. 2021 (307)
  6. 2020 (307)

More Years

Publications
  1. Journal of Clinical Oncology (547)
  2. Blood (248)
  3. Annals of Oncology (98)
  4. Clinical Cancer Research (95)
  5. Journal of Thoracic Oncology (82)
  6. Cancer Research (80)

More Publications

Publishers
  1. American Society of Clinical Oncology (618)
  2. Elsevier Inc. (355)
  3. American Society of Hematology (282)
  4. American Association for Cancer Research (217)
  5. Nature Publishing Group (177)
  6. Oxford University Press (147)

More Publishers

Results (2567)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: Safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells
    Meeting Abstract

    Foy, S.; Jacoby, K.; Bota, D.; Hunter, T.; Schoenfeld, A.; Pan, Z.; Stawiski, E.; Ma, Y.; Lu, W.; Peng, S. M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A reproducible pipeline for analysis of multiplex imaging (MIBI) data with application to uncovering novel features of the tumorimmune microenvironment
    Meeting Abstract

    Maxey, J.; Thompson, M.; Campbell, K.; Kamphaus, B.; Bustami, Z.; Santulli-Marotto, S.; Wells, D.; Boffo, S.; Salvador, L.; Scumpia, P.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1/2 open-label study (IOV-GM1-201) of talen-mediated PD-1-inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
    Meeting Abstract

    Betof, A.; Wise-Draper, T.; He, K.; Sarnaik, A.; Thompson, J.; Finckenstein, F.; Hari, P.; Jagasia, M.; Desai, A.; Suzuki, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immune checkpoint blockade enhances cyclophosphamide induced anti-tumor immunity in a preclinical melanoma model
    Meeting Abstract

    George, M.; Betof, A.; Merghoub, T.; Hamadene, L.; Hirschhorn, D.; Houghton, A.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • ITIL-306-201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor
    Meeting Abstract

    Ward, J.; Ghobadi, A.; Liao, J.; Schoenfeld, A.; Tykodi, S.; Jiang, Y.; Le Gall, J.; Alvarez-Rodriguez, R.; Sherman, M.; Singson, T.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Exploratory platform trial to evaluate immunotherapy combinations with chemotherapy for the treatment of patients with previously untreated metastatic pancreatic adenocarcinoma (REVOLUTION)
    Meeting Abstract

    Lyman, J.; O'Reilly, E.; Wainberg, Z.; Fisher, G.; Wolff, R.; Ko, A.; O'Hara, M.; Singh, H.; Amaravadi, R.; Kimmelman, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
    Meeting Abstract

    Chung, C.; Colevas, D.; Adkins, D.; Park, J. C.; Rodriguez, C.; Gibson, M.; Sukari, A.; Burtness, B.; Johnson, F.; Julian, R.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
    Meeting Abstract

    Sanborn, R.; Gabrail, N.; Carneiro, B.; O'Hara, M.; Bordoni, R.; Gordon, M.; Khalil, D.; Hauke, R.; Taglienti, C.; Rogalski, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: Part 1 results
    Meeting Abstract

    Friedman, C.; Carvajal, R.; Davar, D.; Castanon, E.; Ascierto, P.; Calvo, E.; O'Hara, M.; Powell, S.; Shapira-Frommer, R.; Garralda, E.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma
    Meeting Abstract

    Afeyan, A.; Oliveira, G.; Egloff, A. M.; Zeng, Z.; Chernock, R.; Zhou, L.; Messier, C.; Lizotte, P.; Wolff, J.; Pfaff, K.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save